Close Menu

In early online publication in Nature, Harvard's Bill Hahn is senior author on work that used an RNAi screen to find synthetic lethal partners of oncogenic KRAS -- "gene products that, when inhibited, result in cell death only in the presence of an oncogenic allele." They found that the IkappaB kinase TBK1 was needed in cells with mutant KRAS, and by suppressing this gene they induced apoptosis in human cancer cells that depend on oncogenic KRAS expression.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.